enGene Holdings (ENGN) has released an update.
EnGene Holdings Inc. has announced a $200 million private placement of 20 million shares at $10 each, with plans to close the deal by February 16, 2024. This strategic move aims to raise funds for the advancement of EG-70, their key genetic medicine candidate for bladder cancer treatment, as well as for general corporate purposes. Concurrently, CEO Jason Hanson has agreed to continue his executive roles until a successor is found, following which he will transition to a consulting role. The company is actively searching for a new CEO, with Hanson’s resignation attributed to personal reasons, not company disputes.
For further insights into ENGN stock, check out TipRanks’ Stock Analysis page.